(Q37803526)

23 August 2017

Assessing the clinical utility of diagnostics used in drug therapy (English)

1 reference

23 August 2017

0 references

J Woodcock

1

1 reference

PubMed ID

20981005

23 August 2017

language of work or name

English

0 references

publication date

27 October 2010

1 reference

Clinical Pharmacology & Therapeutics

23 August 2017

1 reference

23 August 2017

88

1 reference

23 August 2017

765-773

1 reference

23 August 2017

6

1 reference

Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact

23 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Overview of biomarkers and surrogate endpoints in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Strategic paths for biomarker qualification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Use of genomic signatures in therapeutics development in oncology and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Expanding the orbit of primary prevention--moving beyond JUPITER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Pharmacogenetics--tailoring treatment for the outliers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

Chutes and ladders on the critical path:comparative effectiveness, product value, and the use of biomarkers in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

inferred from DOI database lookup

7 January 2021

based on heuristic

Sex or survival: trade-offs between quality and quantity of life

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.230

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2010.230

1 reference

release_fg2l3ldqqbfmbdp74mgwnt6kpq

23 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fg2l3ldqqbfmbdp74mgwnt6kpq

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

20981005

1 reference

PubMed ID

20981005